Skip to main content

Table 1 Demographic characteristics of the included 93MS women with 116 pregnancies

From: Outcomes of pregnancy in Egyptian women with multiple sclerosis in the new treatment era: a multi-center retrospective observational study

Characteristic Value
Age (mean, SD), years 32.74 ± 5.12
Disease duration, median (IQR), years 4.5 (1.93–8.92)
MS subtype at onset of pregnancy, no. (%)  
 RRMS 109 (93.96%)
 Progressive, relapsing MS 7 (6.03%)
Relapses during 2 years before pregnancya  
 0 52 (44.83%)
 1 43 (37.07%)
 ≥ 2 21 (18.10%)
MS-related disability, no. (%)  
 No disability 70 (60.34%)
 Some disability but fully ambulatory 37 (31.89%)
 Some ambulatory impairment 7 (6.03%)
 Cane required 1 (0.86%)
 Wheelchair required 1 (0.86%)
EDSS score before pregnancy, no. (%)  
 0–0.5 56 (48.27%)
 1–1.5 39 (33.63%)
 2–2.5 14 (12.07%)
 3–3.5 5 (4.31%)
 ≥ 4 2 (1.72%)
DMT use before pregnancy, no. (%)  
 Never 18 (15.52%)
 At the time of conception 23 (19.83%)
 Within 1 year prior 75 (64.65%)
Type used within 1 year prior  
 Interferon-beta 39 (33.62%)
 Dimethyl fumarate 7 (6.03%)
 Natalizumab 1 (0.86%)
 Rituximab 9 (7.76%)
 Ocrelizumab 4 (3.45%)
 Fingolimod 13 (11.21%)
 Teriflunomide 2 (1.72%)
Comorbidities other than MS  
 Hypertension 8 (6.89%)
 Diabetes mellitus 1 (0.86%)
 Othersa 1 (0.86%)
  1. DMT disease-modifying therapy; IQR interquartile range; MS multiple sclerosis; RRMS relapsing–remitting MS; EDSS Expanded Disability Status Scale
  2. aOne case with deep venous thrombosis